You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Systematic review of influenza resistance to the neuraminidase inhibitors
|
|---|---|
| Published in |
BMC Infectious Diseases, May 2011
|
| DOI | 10.1186/1471-2334-11-134 |
| Pubmed ID | |
| Authors |
Kristian Thorlund, Tahany Awad, Guy Boivin, Lehana Thabane |
| Abstract |
Antivirals play a critical role in the prevention and the management of influenza. One class of antivirals, neuraminidase inhibitors (NAIs), is effective against all human influenza viruses. Currently there are two NAI drugs which are licensed worldwide: oseltamivir (Tamiflu®) and zanamivir (Relenza®); and two drugs which have received recent approval in Japan: peramivir and laninamivir. Until recently, the prevalence of antiviral resistance has been relatively low. However, almost all seasonal H1N1 strains that circulated in 2008-09 were resistant to oseltamivir whereas about 1% of tested 2009 pandemic H1N1 viruses were found to be resistant to oseltamivir. To date, no studies have demonstrated widespread resistance to zanamivir. It seems likely that the literature on antiviral resistance associated with oseltamivir as well as zanamivir is now sufficiently comprehensive to warrant a systematic review.The primary objectives were to systematically review the literature to determine the incidence of resistance to oseltamivir, zanamivir, and peramivir in different population groups as well as assess the clinical consequences of antiviral resistance. |
Mendeley readers
The data shown below were compiled from readership statistics for 171 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | <1% |
| Germany | 1 | <1% |
| Ireland | 1 | <1% |
| China | 1 | <1% |
| Japan | 1 | <1% |
| Unknown | 166 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 34 | 20% |
| Student > Ph. D. Student | 18 | 11% |
| Student > Master | 18 | 11% |
| Student > Bachelor | 18 | 11% |
| Other | 13 | 8% |
| Other | 43 | 25% |
| Unknown | 27 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 26% |
| Agricultural and Biological Sciences | 37 | 22% |
| Chemistry | 19 | 11% |
| Biochemistry, Genetics and Molecular Biology | 13 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 5% |
| Other | 18 | 11% |
| Unknown | 32 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2022.
All research outputs
#4,823,325
of 23,269,984 outputs
Outputs from BMC Infectious Diseases
#1,593
of 7,791 outputs
Outputs of similar age
#24,569
of 113,079 outputs
Outputs of similar age from BMC Infectious Diseases
#14
of 54 outputs
Altmetric has tracked 23,269,984 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,791 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 113,079 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.